ORIC Pharmaceuticals (FRA:4TZ) Loans Receivable: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4TZ ORIC Pharmaceuticals Inc FRA:4TZ
34 GF Score
Price €11.41
! 4 Warning Signs
View Full Analysis

What is ORIC Pharmaceuticals Loans Receivable?

ORIC Pharmaceuticals FRA:4TZ -1.43% 34 Loans Receivable is €0.00 Mil as of Jun. 2026. GuruFocus rates FRA:4TZ with a GF Score™ of 34/100. The stock has 4 warning signs investors should review.

ORIC Pharmaceuticals's Loans Receivable for the quarter that ended in Jun. 2026 was €0.00 Mil.

ORIC Pharmaceuticals Loans Receivable Related Terms

ORIC Pharmaceuticals Loans Receivable Historical Data

* Premium members only.

The historical data trend for ORIC Pharmaceuticals's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ORIC Pharmaceuticals Loans Receivable Chart

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

ORIC Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:4TZ
34GF Score
ORIC Pharmaceuticals Inc FRA:4TZ
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ORIC Pharmaceuticals Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0.00 Mil mean?
ORIC Pharmaceuticals (FRA:4TZ) has a Loans Receivable of €0.00 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on ORIC Pharmaceuticals and its competitors.
Is ORIC Pharmaceuticals' Loans Receivable too high?
ORIC Pharmaceuticals' current Loans Receivable is €0.00 Mil. Overall, ORIC Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does ORIC Pharmaceuticals' Loans Receivable compare to ARDX and IMTX?
ORIC Pharmaceuticals' Loans Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on ORIC Pharmaceuticals and its competitors. ORIC Pharmaceuticals's current Loans Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ORIC Pharmaceuticals stock overvalued right now?
ORIC Pharmaceuticals (FRA:4TZ) has a current Loans Receivable of €0.00 Mil. The current Loans Receivable is €0.00 Mil. ORIC Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For ORIC Pharmaceuticals (FRA:4TZ), the current Loans Receivable is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ORIC Pharmaceuticals Business Description

Other Exchanges ORIC:USA
Address 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
34GF Score

Get the complete analysis for FRA:4TZ

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.41
Price